BioCentury
ARTICLE | Financial News

Y-mAbs aiming for $92M IPO

August 24, 2018 10:14 PM UTC

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG.

Y-mAbs hopes to submit BLAs next year for two antibodies that are now in pivotal trials to treat pediatric neuroblastoma indications. Each program has Orphan Drug, rare pediatric disease and breakthrough therapy designations...

BCIQ Company Profiles

Y-mAbs Therapeutics Inc.